Technology | May 03, 2011

FDA Clears Cardiac/Respiratory Assist Device

May 3, 2011 – The U.S. Food and Drug Administration (FDA) has given 510(k) clearance to Maquet Cardiovascular’s Cardiohelp system as a cardiac and/or respiratory assist device for up to six hours. The system is the world's smallest portable heart-lung support system providing extracorporeal life support (ECLS) to replace or support a patient's circulation and respiration.

The product is expected to be commercially available in the United States later this year.

"Cardiovascular disease is the leading cause of death globally, with an estimated 17.5 million deaths each year," said Jeremy Cannon, M.D., trauma surgeon at Brooke Army Medical Center in San Antonio, Texas. "Many of these individuals experience cardiogenic shock because vital organs are not adequately supplied with oxygen. By quickly connecting a patient to a cardiopulmonary support system, the Cardiohelp System will allow clinicians to gain valuable time that could save the patient's life."

The system, which includes the HLS Advanced Tubing Set, is the first support system approved for both ground and air transportation. It is light enough to be carried by one person and compact enough to be transported in a helicopter or vehicle. With its disposables, integrated sensors and individual operating modes, it provides new options for patients whose heart and/or lungs are failing despite other treatment options.

"The need for immediate, mobile, compact, life-sustaining resuscitation occurs on a daily basis, both in and outside the hospital," said Linda Mongero CCP, perfusionist at New York Presbyterian Hospital. "Cardiohelp is a collective system of engineering that finally optimizes cardiopulmonary support in prime time."

The individual operating modes and disposables make it suitable for conditions in which cardiac and/or respiratory support is needed. The system offers several applications to support patients who require veno-venous life support or veno-arterial life support. It can also be used during open heart surgery and for extracorporeal carbon dioxide (CO2) removal up to six hours.

Veno-venous life support, or respiratory assistance for lung disorders, is primarily used when the heart is still able to pump blood through the circulatory system without any additional support, as in the case of acute respiratory failure or a massive pulmonary embolism. The blood is removed from the jugular vein or a femoral vein for enrichment with oxygen, after which it is returned to a vein.

Veno-arterial life support is used with patients whose hearts are not adequately supporting their circulation or have stopped, which may occur with a myocardial infarction. It is vital to ensure cardiopulmonary support as early as possible to prevent organ damage. The system can help increase survival by enabling revascularization by means of catheterization or cardiac surgery. In the case of a veno-arterial life support, the blood is removed from the right atrium or a femoral vein and is returned to the aorta or a femoral artery after oxygenation. Some of the blood therefore bypasses the heart in a parallel circulatory system, thus relieving stress on the heart muscle.

In severe cases of respiratory failure, it can be used to reduce the CO2 level in the blood. High CO2 levels (e.g., acidosis, pulmonary hypertension) in some cases can lead to complications, and some patients need low to normal CO2 levels to protect the brain.

Minimal extracorporeal circulation (MECC) with the system makes life support for cardiopulmonary support during open heart surgery less stressful for the patient than with a conventional heart-lung machine.

The system may be installed in ambulances or helicopters and can be connected to the on-board power supply. The integrated rechargeable battery also provides a minimum of 90 minutes of operation without an external power supply. It is operated via an easy touch screen with user guidance and a rotary knob to allow medical personnel with minimal life support experience to safely use the unit after suitable training.

It monitors important blood parameters, including venous oxygen saturation, hemoglobin, hematocrit and arterial and venous blood temperature. The complete sensor system, which also includes three pressure sensors, is integrated into the HLS Module Advanced disposable.

The system can be configured to capture case data and data recording intervals can be set individually from 3 seconds to 10 minutes.

For more information:,

Related Content

Aortix device, TCT, Interventional Innovation Shark Tank Competition, catheter-based circulatory heart pump

Image courtesy of Procyrion

News | Ventricular Assist Devices (VAD)| October 06, 2015
The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in...
Procyrion, Aortix device, grand prize, Create the Future Design Contest

Aortix device image courtesy of Procyrion Inc.

News | Ventricular Assist Devices (VAD)| October 05, 2015
Procyrion Inc. of Houston has been awarded the grand prize of $20,000 in the 2015 "Create the Future" Design Contest...
Freedom Driver, SynCardia, recall, Total Artificial Heart, TAH-t, part failure

Freedom Driver attached to Total Artificial Heart. Image courtesy of SynCardia.

News | Ventricular Assist Devices (VAD)| September 18, 2015
SynCardia Systems initiated a Class I recall of the Freedom Driver Systems used with the company’s temporary Total...
Thoratec, HeartMate II LVAS, Urgent Device Correction Letter, Pocket System Controller, backup battery
News | Ventricular Assist Devices (VAD)| September 16, 2015
Thoratec Corp. issued a voluntary Urgent Medical Device Correction Letter to all hospitals who have patients supported...
Maquet, extracorporeal life support, ECLS, cardiogenic shock, bridge-to-life, PLS system

PLS system image courtesy of Maquet

News | ECMO Systems| September 08, 2015
In a new study reported in The Journal of Thoracic and Cardiovascular Surgery, researchers found a dramatic difference...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
FDA, warning, LVADs, left ventricular assist devices, Thoratec, HeartMate II, HeartWare, HVAD
News | Ventricular Assist Devices (VAD)| August 06, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers, patients and caregivers about serious...
HeartWare, ventricular assist device, HeartWare VAD, recall, update
News | Ventricular Assist Devices (VAD)| August 05, 2015
HeartWare expanded the Class I recall of its ventricular assist device in mid-June due to concerns over damaged or...
LVADs, heart failure patients, echocardiography, ASE, recommendations, guideline
News | Cardiovascular Ultrasound| August 04, 2015
Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given...
Overlay Init